EPCORE DLBCL-1 is a global, Phase 3, open label, multi-center, randomized clinical trial with prespecified primary endpoints that differ by region. In the United States, where overall survival (OS) is the sole primary endpoint, the study did not demonstrate a statistically significant improvement in OS and therefore did not meet its primary endpoint.
https://finance.yahoo.com/healthcare/articles/genmab-abbvie-clarification-phase-3-200000241.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.